Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Sophiris Bio
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Lower Urinary Tract Symptoms|Prostatic Hyperplasia
Phase 2: Prostate Cancer|Prostatic Hyperplasia|Lower Urinary Tract Symptoms
Phase 1: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12618001303235p |
SPPH | N/A |
Not yet recruiting |
Breast Cancer|Vascular Cancer|Breast Diseases |
None |
|||
NCT00379561 |
PRX302 | P1 |
Completed |
Prostate Cancer |
2007-05-01 |
2019-03-21 |
Treatments |
|
2016-004694-41 |
Intraprostatic PRX302 injection to treat localised prostate cancer | P2 |
Terminated |
Prostate Cancer |
2018-11-30 |
2022-03-13 |
||
NCT03081481 |
PRX302-2-08 | P2 |
Completed |
Prostate Cancer |
2018-11-28 |
2019-04-11 |
||
NCT02499848 |
PRX302-2-07 | P2 |
Completed |
Prostate Cancer |
2016-06-01 |
2019-03-20 |
Treatments |
|
2014-003386-22 |
Intraprostatic PRX302 injection to treat localised prostate cancer | P2 |
Completed |
Prostate Cancer |
2016-05-11 |
2022-03-13 |
Treatments |
|
NCT01454349 |
PRX302-2-06 | P2 |
Completed |
Lower Urinary Tract Symptoms|Prostatic Hyperplasia |
2013-03-01 |
2019-03-19 |
Treatments |
|
NCT00889707 |
TRIUMPH-1 | P2 |
Completed |
Prostatic Hyperplasia |
2009-12-01 |
2019-03-18 |
Treatments |
|
NCT00686088 |
PRX302-1-02 | P2 |
Completed |
Prostate Cancer |
2009-09-01 |
2019-03-18 |
Treatments |
|
NCT01966614 |
PLUS-1 | P3 |
Completed |
Lower Urinary Tract Symptoms|Prostatic Hyperplasia |
2015-12-01 |
2019-03-20 |